Ding Shanshan, Long Fei, Jiang Shujuan
Department of Respiratory Medicine, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China.
Oncol Lett. 2016 Jun;11(6):4240-4244. doi: 10.3892/ol.2016.4508. Epub 2016 Apr 28.
Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is an oral targeted anticancer drug that is used to treat non-small cell lung cancer (NSCLC). Previous studies have confirmed that erlotinib is safe and is well-tolerated by patients. The most common adverse reactions observed following erlotinib treatment include a rash and mild diarrhea. In the current study, the first case of acute myocardial infarction following one month of treatment with erlotinib in a 63-year-old male NSCLC patient is presented. The present study highlights the importance of clinicians remaining cautious following erlotinib administration. In elderly NSCLC patients and those with a history of coronary heart disease, cardiac function must be carefully monitored following erlotinib treatment so that serious adverse reactions, such as myocardial infarction, may be identified early and treated quickly.
厄洛替尼是一种表皮生长因子受体酪氨酸激酶抑制剂，是一种用于治疗非小细胞肺癌（NSCLC）的口服靶向抗癌药物。先前的研究证实，厄洛替尼是安全的，患者耐受性良好。厄洛替尼治疗后观察到的最常见不良反应包括皮疹和轻度腹泻。在本研究中，报告了一名63岁男性非小细胞肺癌患者在接受厄洛替尼治疗一个月后发生急性心肌梗死的首例病例。本研究强调了临床医生在给予厄洛替尼后保持谨慎的重要性。在老年非小细胞肺癌患者和有冠心病病史的患者中，厄洛替尼治疗后必须仔细监测心功能，以便早期发现并快速治疗心肌梗死等严重不良反应。
